596 related articles for article (PubMed ID: 27424083)
1. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo.
Maisel K; Reddy M; Xu Q; Chattopadhyay S; Cone R; Ensign LM; Hanes J
Nanomedicine (Lond); 2016 Jun; 11(11):1337-43. PubMed ID: 27171816
[TBL] [Abstract][Full Text] [Related]
3. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.
Xu Q; Ensign LM; Boylan NJ; Schön A; Gong X; Yang JC; Lamb NW; Cai S; Yu T; Freire E; Hanes J
ACS Nano; 2015 Sep; 9(9):9217-27. PubMed ID: 26301576
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.
Schaefer A; Yang B; Schroeder HA; Harit D; Humphry MS; Ravel J; Lai SK
Acta Biomater; 2023 Oct; 169():387-397. PubMed ID: 37499728
[TBL] [Abstract][Full Text] [Related]
5. PEGylation for enhancing nanoparticle diffusion in mucus.
Huckaby JT; Lai SK
Adv Drug Deliv Rev; 2018 Jan; 124():125-139. PubMed ID: 28882703
[TBL] [Abstract][Full Text] [Related]
6. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated trapping in biological hydrogels is governed by sugar-sugar hydrogen bonds.
Schiller JL; Fogle MM; Bussey O; Kissner WJ; Hill DB; Lai SK
Acta Biomater; 2020 Apr; 107():91-101. PubMed ID: 32147470
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.
Yang M; Lai SK; Yu T; Wang YY; Happe C; Zhong W; Zhang M; Anonuevo A; Fridley C; Hung A; Fu J; Hanes J
J Control Release; 2014 Oct; 192():202-8. PubMed ID: 25090196
[TBL] [Abstract][Full Text] [Related]
9. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo.
Grenier P; Viana IMO; Lima EM; Bertrand N
J Control Release; 2018 Oct; 287():121-131. PubMed ID: 30138715
[TBL] [Abstract][Full Text] [Related]
10. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
[TBL] [Abstract][Full Text] [Related]
11. [Induction of Anti-PEG Immune Responses by PEGylation of Proteins].
Shimizu T; Ishima Y; Ishida T
Yakugaku Zasshi; 2020; 140(2):163-169. PubMed ID: 32009039
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.
Lai SK; Wang YY; Hida K; Cone R; Hanes J
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):598-603. PubMed ID: 20018745
[TBL] [Abstract][Full Text] [Related]
13. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
14. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.
Chen WA; Chang DY; Chen BM; Lin YC; Barenholz Y; Roffler SR
ACS Nano; 2023 Mar; 17(6):5757-5772. PubMed ID: 36926834
[TBL] [Abstract][Full Text] [Related]
16. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus.
Lai SK; Suk JS; Pace A; Wang YY; Yang M; Mert O; Chen J; Kim J; Hanes J
Biomaterials; 2011 Sep; 32(26):6285-90. PubMed ID: 21665271
[TBL] [Abstract][Full Text] [Related]
17. pH-Responsive Mucus-Penetrating Nanoparticles for Enhanced Cellular Internalization by Local Administration in Vaginal Tissue.
Zhang Y; Li S; Loch K; Duncan GA; Kaler L; Pangeni R; Peng W; Wang S; Gong X; Xu Q
ACS Macro Lett; 2023 Apr; 12(4):446-453. PubMed ID: 36951898
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population.
Yang Q; Jacobs TM; McCallen JD; Moore DT; Huckaby JT; Edelstein JN; Lai SK
Anal Chem; 2016 Dec; 88(23):11804-11812. PubMed ID: 27804292
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus.
Ensign LM; Lai SK; Wang YY; Yang M; Mert O; Hanes J; Cone R
Biomacromolecules; 2014 Dec; 15(12):4403-9. PubMed ID: 25347518
[TBL] [Abstract][Full Text] [Related]
20. Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus.
Xu Q; Boylan NJ; Cai S; Miao B; Patel H; Hanes J
J Control Release; 2013 Sep; 170(2):279-86. PubMed ID: 23751567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
